Section Arrow
OABI.NASDAQ
- OmniAb
Quotes are at least 15-min delayed:2026/06/02 20:07 EDT
Regular Hours
Last
 2.62
+0.01 (+0.38%)
Day High 
2.74 
Prev. Close
2.61 
1-M High
2.79 
Volume 
757.55K 
Bid
2.62
Ask
2.71
Day Low
2.5511 
Open
2.57 
1-M Low
1.3502 
Market Cap 
378.38M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.56 
20-SMA 2.14 
50-SMA 1.77 
52-W High 2.79 
52-W Low 1.3 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.46/-0.22
Enterprise Value
394.83M
Balance Sheet
Book Value Per Share
1.81
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
18.67M
Operating Revenue Per Share
0.46
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.1098-0.0032-2.83%-- 
FULCFulcrum Therapeutics3.14-3.28-51.09%-- 
AIMAIM ImmunoTech Inc.0.8267-0.0719-8.00%-- 
EVGNEvogene Ltd.0.5901-0.0929-13.60%-- 
HRTXHeron Therapeutics0.45-0.3772-45.60%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.